Prognostification of ALL by Cytogenetics

Area of Science:

• Pediatric Oncology
• Cancer Genetics
• Molecular Biology

Background:

• Cytogenetic abnormalities are frequent in pediatric acute lymphoblastic leukemia (ALL).
• These abnormalities can influence treatment response and patient outcomes.
• Methotrexate metabolism is linked to cytogenetic status and treatment efficacy.

Purpose of the Study:

• To explore the prognostic significance of cytogenetic abnormalities in pediatric ALL.
• To investigate the association between cytogenetic status, methotrexate metabolism, and treatment response.
• To identify specific chromosomal alterations linked to favorable or unfavorable outcomes.

Main Methods:

• Analysis of cytogenetic abnormalities in pediatric ALL patient samples.
• Assessment of methotrexate (MTX) and MTX polyglutamate levels in lymphoblasts.
• Evaluation of basal apoptotic rates in leukemic cells with varying ploidy.
• Correlation of cytogenetic findings with clinical outcomes and treatment response.

Main Results:

• Hyperdiploid lymphoblasts accumulate higher levels of MTX and MTX polyglutamates.
• These cells exhibit increased basal apoptotic rates compared to lower ploidy or normal cells.
• Favorable outcomes are associated with high hyperdiploidy (51-65 chromosomes) and ETV6-RUNX1 fusion.
• Poor prognosis is linked to the Philadelphia chromosome [t(9;22)], MLL gene rearrangements, and iAMP21.

Conclusions:

• Hyperdiploidy in pediatric ALL contributes to better outcomes via enhanced MTX efficacy and apoptosis.
• Specific cytogenetic abnormalities, including ETV6-RUNX1, t(9;22), MLL rearrangements, and iAMP21, are critical prognostic markers.
• Understanding these genetic factors is crucial for tailoring treatment strategies in pediatric ALL.